Australian biotech market watch 19/06/09
Friday, 19 June, 2009
The All Ordinaries has had a turbulent week, shedding some of the gains made in the previous seven days, although Friday was mainly level, with the All Ords sitting at 3190 at 4:15pm on Friday.
Contrasting the flagging performance of the All Ordinaries, the health indices are up on Friday nearly 1.5% from last week.
CSL (ASX:CSL), the smallest of the six big vaccine makers worldwide, is pipped to have a swine flu vaccine first, and this optimism has resulted in some lifts in CSL's share price over the last few weeks. Today it's up 42c to $31.55.
Cochlear (ASX:COH) has gone through a few wobbles this week, finishing on $56.84, only a few cents off its start on Monday of $56.92.
Amongst the losers is Ansell (ASX:ANN), down 1.6% to $8.80, and Blackmores (ASX:BKL), dropping 4.7% after riding high on the threats from swine flu, which appear to be subsiding with the federal government reducing the alert level on Wednesday.
Novogen (ASX:NRT) has also slipped another 13% today to 62c, down a full 40% from its peak on May 19 of $1.02.
Ramsay Health Care has seen a slight slide over the last couple of days down to $11.07.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
